The first transfemoral balloon-expandable transcatheter heart valve for pure native aortic regurgitation (PNAR) shows a low incidence of adverse safety events and good clinical outcomes at 30 days, with notably low rates of paravalvular leak and permanent pacemaker implantation (PPI), early trial data suggests.